Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Fiverr International Ltd (FVRR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Fiverr International Ltd — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.74 (market cap $4.49B), while Fiverr International Ltd trades at $10.86 (market cap $403.37M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 11.1× Fiverr International Ltd's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals.
| ACAD | FVRR | |
|---|---|---|
Market Cap | $4.49B | $403.37M |
Sector | Health | Industrials |
52-Week High | $28.06 | $27.77 |
52-Week Low | $20.06 | $9.62 |
Enterprise Value | $3.69B | $133.97M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Fiverr International (FVRR) trades at $11.22, up 3.79% today, showing signs of recovery from recent lows. The stock appears fundamentally undervalued with a P/E of 14.44 and P/S of 0.96, while revenue growth has been steady from $337M in 2022 to $431M in 2025. Recent earnings show mixed results with Q1 2026 missing expectations, but technical indicators suggest bullish momentum with strong moving average support.
FVRR presents a contrarian opportunity with attractive valuation metrics and improving profitability, though investor sentiment remains cautious due to active buyer declines and ongoing legal investigations. The company's strategy shift and strong gross margins of 81.86% provide upside potential, but competitive pressures and execution risks require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →
